Recently, immunotherapy has achieved success in treating various cancers. Immune-mediated cell death is key in improving immunotherapy clinical outcomes. Nevertheless, many patients with cancer fail to respond to immunotherapy because of a lack of tumor-infiltrating lymphocytes (TILs). Inflammatory cell death, such as PANoptosis, necroptosis, and pyroptosis, has been shown to remodel the tumor immune milieu and enrich TILs. Meanwhile, promoting the inflammatory death of tumor cells does help to construct an immunotherapy-responsive state. The inflammatory tumor microenvironment plays an important role in reconstructing the tumor microenvironment and enhancing the efficacy of immunotherapy. A greater understanding of the relationship between inflammatory cell death and the tumor microenvironment may lead to the development of novel strategies for cancer treatments and patient outcomes.
This research topic aims to provide an advanced forum for how the inflammatory death of tumor cells reprograms the tumor immune microenvironment and tumor development. Alternatively, this novel research does help to find new molecular targets and approaches for cancer diagnosis, prognosis, and treatment.
Original research articles and reviews are welcome. Specific areas of interest for the topic include, but are not limited to, the following:
- Emerging mechanisms of inflammatory cell death and its therapeutic strategy in cancer development and progression;
- Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
- Identifying inflammatory cell death regulators, such as genes, proteins, and transcription factors, as novel targets for cancer prognosis and immunotherapy response;
- Combination therapy of tumor inflammatory cell death inducers and tumor immunity;
- Nanomedicine for cancers based on inflammatory cell death;
- Bioinformatics and computational biology methods to evaluate the role of inflammatory cell death in modulating the tumor immune microenvironment.
Recently, immunotherapy has achieved success in treating various cancers. Immune-mediated cell death is key in improving immunotherapy clinical outcomes. Nevertheless, many patients with cancer fail to respond to immunotherapy because of a lack of tumor-infiltrating lymphocytes (TILs). Inflammatory cell death, such as PANoptosis, necroptosis, and pyroptosis, has been shown to remodel the tumor immune milieu and enrich TILs. Meanwhile, promoting the inflammatory death of tumor cells does help to construct an immunotherapy-responsive state. The inflammatory tumor microenvironment plays an important role in reconstructing the tumor microenvironment and enhancing the efficacy of immunotherapy. A greater understanding of the relationship between inflammatory cell death and the tumor microenvironment may lead to the development of novel strategies for cancer treatments and patient outcomes.
This research topic aims to provide an advanced forum for how the inflammatory death of tumor cells reprograms the tumor immune microenvironment and tumor development. Alternatively, this novel research does help to find new molecular targets and approaches for cancer diagnosis, prognosis, and treatment.
Original research articles and reviews are welcome. Specific areas of interest for the topic include, but are not limited to, the following:
- Emerging mechanisms of inflammatory cell death and its therapeutic strategy in cancer development and progression;
- Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy
- Identifying inflammatory cell death regulators, such as genes, proteins, and transcription factors, as novel targets for cancer prognosis and immunotherapy response;
- Combination therapy of tumor inflammatory cell death inducers and tumor immunity;
- Nanomedicine for cancers based on inflammatory cell death;
- Bioinformatics and computational biology methods to evaluate the role of inflammatory cell death in modulating the tumor immune microenvironment.
